ArticleIranian journal of pathology2024
Histopathological Evaluation of PYGO2 Expression in Esophageal Squamous Cell Carcinoma.
Article in Iranian journal of pathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Objective: Esophageal squamous cell carcinoma (ESCC) is one of the world's deadliest cancer diseases. Deregulation of developmental signaling pathways such as Wnt/β-catenin is frequently implicated in a wide range of human cancers. The present study was designed to analyze the expression of the Pygopus2 (PYGO2) protein, the main co-activator of the Wnt/β-catenin signaling pathway, in ESCC tissues and evaluate its probable correlation with clinicopathological features of patients. Methods: In this study, PYGO2 protein expression was assessed in tumors and margin normal tissues from 50 ESCC patients using immunohistochemical analysis, and its clinicopathological relevance in the patients was evaluated. Results: A significant PYGO2 overexpression was observed in %32 of the tumor cells. Interestingly, PYGO2 expression was significantly correlated with the depth of tumor invasion ( Conclusion: PYGO2 protein may be highly expressed in ESCC in correlation with the invasiveness of the disease. Therefore, it may be used as a biomarker for diagnosis of invasive ESCC and a putative therapeutic target to inhibit ESCC invasiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.